EICHORCondition: Hepatocellular Carcinoma · Sponsor: Genentech, Inc.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Arizona Cancer Center | Tucson, Arizona, United States | — |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | — |
| University of Southern California-Keck School of Medicine -1975 Zonal Ave | Los Angeles, California, United States | — |
| University of Southern California | Newport Beach, California, United States | — |
| University of California Irvine Medical Center | Orange, California, United States | — |
| California Liver Research Institute | Pasadena, California, United States | — |
| University of California Davis Medical Center | Sacramento, California, United States | — |
| Stanford Health Care | Stanford, California, United States | — |
| Harbor UCLA Medical Center | Torrance, California, United States | — |
| Cedars Sinai Comprehensive Transplant Center | West Hollywood, California, United States | — |
| Rocky Mountain Cancer Centers (Williams) - USOR | Denver, Colorado, United States | — |
| Hartford Healthcare Cancer Institute at Hartford Hospital | Hartford, Connecticut, United States | — |
+ 47 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06096779